Scarica l'app Stockscreener
1.49
0.00%
0.00
Dopo l'orario di chiusura:
1.52
0.03
+2.01%
Panoramica
Notizia
Cronologia dei prezzi
Financials
Perché ITRM Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$1.49
Aprire:
$1.5
Volume 24 ore:
315.72K
Relative Volume:
0.34
Capitalizzazione di mercato:
$51.53M
Reddito:
-
Utile/perdita netta:
$-35.58M
Rapporto P/E:
-0.5623
EPS:
-2.65
Flusso di cassa netto:
$-42.82M
1 W Prestazione:
-3.25%
1M Prestazione:
-1.97%
6M Prestazione:
+14.18%
1 anno Prestazione:
+3.47%
Intervallo 1D:
$1.4635
$1.54
Intervallo di 1 settimana:
$1.42
$1.5589
Portata 52W:
$0.808
$3.02
Iterum Therapeutics Plc Stock (ITRM) Company Profile
Nome
Iterum Therapeutics Plc
Settore
Industria
Telefono
(872) 225-6077
Indirizzo
3 DUBLIN LANDINGS, DUBLIN 1
Confronta ITRM con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ITRM
Iterum Therapeutics Plc
|
1.49 | 51.53M | 0 | -35.58M | -42.82M | -2.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Iterum Therapeutics Plc Stock (ITRM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-05-28 | Aggiornamento | Gabelli & Co | Sell → Hold |
| 2021-03-15 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2020-06-02 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-01-21 | Downgrade | Gabelli & Co | Buy → Sell |
| 2019-12-11 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2019-06-21 | Iniziato | H.C. Wainwright | Buy |
Mostra tutto
Iterum Therapeutics Plc Borsa (ITRM) Ultime notizie
Iterum Therapeutics plc (NASDAQ:ITRM) Short Interest Down 5.3% in January - Defense World
Iterum Therapeutics faces Nasdaq non-compliance issue - MSN
A stock that deserves closer examination: Iterum Therapeutics Plc (ITRM) - US Post News
Iterum Therapeutics Plc [ITRM] Insider Activity: An Update for Investors - Knox Daily
ITRM Posts Updates From FDA Advisory Meeting for UTI Drug, Stock Down - MSN
A better buy-in window may exist right now for Iterum Therapeutics Plc (ITRM) - SETE News
Iterum Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results -February 10, 2025 at 10:41 am EST - Marketscreener.com
Iterum outlines ORLYNVAH's market potential with exclusivity through 2034 - MSN
Iterum Therapeutics plc (NASDAQ:ITRM) Q4 2024 Earnings Call Transcript - Insider Monkey
Iterum Therapeutics PLC (ITRM) Q4 2024 Earnings Call Highlights: Navigating Financial ... - Yahoo Finance
Iterum Therapeutics Highlights FDA Approval and Financial Progress - TipRanks
Earnings call transcript: Iterum Therapeutics reports Q4 2024 results and stock surges - MSN
Iterum Therapeutics PLC Files For Mixed Shelf Of Up To $150 Million -February 07, 2025 at 04:42 pm EST - Marketscreener.com
Iterum Therapeutics Plc’s Shares Reel: 14.34% Quarterly Revenue Decline Amid 40.59M Market Cap - The InvestChronicle
Iterum Therapeutics PLC reports results for the quarter ended December 31Earnings Summary - TradingView
Iterum Therapeutics plc Reports Earnings Results for the Fourth Quarter Ended December 31, 2024 - Marketscreener.com
Iterum Therapeutics plc (ITRM) reports earnings - Quartz
Iterum Therapeutics plc SEC 10-K Report - TradingView
ForexTV | Small Business Resources - ForexTV.com
Iterum Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results - The Manila Times
Iterum's Landmark UTI Drug ORLYNVAH Powers Financial Turnaround in Q4 Report - StockTitan
Iterum Therapeutics Plc (ITRM) Shares Down Despite Recent Market Volatility - The News Heater
Iterum Therapeutics (ITRM) Expected to Announce Quarterly Earnings on Friday - Defense World
Is Iterum Therapeutics Plc (ITRM) a good investment opportunity? - US Post News
Iterum Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 7, 2025 - Marketscreener.com
Iterum Therapeutics (NASDAQ:ITRM) Stock Quotes, Forecast and News Summary - Benzinga
Iterum Pharmaceuticals Earnings: Q4 Results and Pipeline Updates Coming February 7 - StockTitan
Short Interest in Iterum Therapeutics plc (NASDAQ:ITRM) Drops By 10.3% - Defense World
Iterum Therapeutics to Host Morning Conference Call on U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections - The Eastern Progress Online
Iterum Therapeutics stock hits 52-week high at $2.35 By Investing.com - Investing.com UK
Metrics That Matter About Iterum Therapeutics Plc (NASDAQ: ITRM) - Stocks Register
Iterum Therapeutics Regains Full Nasdaq Compliance - The Manila Times
Iterum Therapeutics to Host Morning Conference Call on U.S. FDA - GuruFocus.com
Iterum Therapeutics plc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Iterum Therapeutics plc (NASDAQ:ITRM) Q3 2024 Earnings Call Transcript - Insider Monkey
Iterum Therapeutics plc (ITRM) Quarterly 10-Q Report - Quartzy
ARMISTICE CAPITAL, LLC Acquires New Stake in Iterum Therapeutics PLC - GuruFocus.com
Iterum Therapeutics PLC (ITRM) Q3 2024 Earnings Call Highlights: Strategic Moves Amid Financial Challenges - GuruFocus.com
Iterum Therapeutics PLC (ITRM) Q3 2024 Earnings Call Highlights: Strategic Moves Amid Financial ... By GuruFocus - Investing.com Canada
Iterum Therapeutics PLC (ITRM) Q3 2024 Earnings Call Highlights: Strategic Moves Amid Financial ... - Yahoo Finance
Iterum Therapeutics’ Strategic Advances with ORLYNVAH Approval - TipRanks
Earnings Flash (ITRM) ITERUM THERAPEUTICS Reports Q3 Loss $-0.24 - Marketscreener.com
Iterum Therapeutics Reports Third Quarter 2024 Financial Results - The Manila Times
Iterum Therapeutics sees cash runway into 2025 - TipRanks
Iterum's ORLYNVAH Gets FDA Nod; Q3 Shows $14.5M Cash Position Amid Wider Losses | ITRM Stock News - StockTitan
Iterum Therapeutics (ITRM) Scheduled to Post Earnings on Thursday - Defense World
A Look at Iterum Therapeutics's Upcoming Earnings Report - Benzinga
Iterum Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024 - The Manila Times
Iterum Therapeutics defers $20 million FDA milestone payment - Investing.com India
Iterum Therapeutics defers $20 million FDA milestone payment By Investing.com - Investing.com Australia
Iterum Therapeutics : Financial Obligation Form 8 K - Marketscreener.com
Iterum Therapeutics Plc Azioni (ITRM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.27%
3.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):